248 related articles for article (PubMed ID: 27989877)
21. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
[TBL] [Abstract][Full Text] [Related]
22. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Pan Y; Li X; Duan J; Yuan L; Fan S; Fan J; Xiaokaiti Y; Yang H; Wang Y; Li X
Mol Pharmacol; 2015; 87(3):378-90. PubMed ID: 25488183
[TBL] [Abstract][Full Text] [Related]
23. Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway.
Chen SY; Zhang GC; Shu QJ
Pharm Biol; 2021 Dec; 59(1):1294-1304. PubMed ID: 34543169
[TBL] [Abstract][Full Text] [Related]
24. Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.
Xiang S; Zhang Q; Tang Q; Zheng F; Wu J; Yang L; Hann SS
Sci Rep; 2016 Nov; 6():36721. PubMed ID: 27830724
[TBL] [Abstract][Full Text] [Related]
25. Fuzheng Kang' ai decoction inhibits cell proliferation, migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells.
Jinhua LI; Chunping L; Yueyang Z; Wanyin WU; Pengtao S; Longmei LI; Xiaobing Y; Yushu Z
J Tradit Chin Med; 2022 Jun; 42(3):344-352. PubMed ID: 35610003
[TBL] [Abstract][Full Text] [Related]
26. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
Wang J; He X; Jia Z; Yan A; Xiao K; Liu S; Hou M; Long Y; Ding X
Pharm Biol; 2024 Dec; 62(1):33-41. PubMed ID: 38100532
[TBL] [Abstract][Full Text] [Related]
27. Traditional Chinese medicine, Fuzheng Kang‑Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway.
Li L; Wang S; Yang X; Long S; Xiao S; Wu W; Hann SS
Mol Med Rep; 2017 Sep; 16(3):2461-2468. PubMed ID: 28677797
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
29. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC
Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348
[TBL] [Abstract][Full Text] [Related]
30. Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.
Han SY; Zhao W; Sun H; Zhou N; Zhou F; An G; Li PP
Phytomedicine; 2015 May; 22(5):560-7. PubMed ID: 25981922
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
Song J; Zhong R; Huang H; Zhang Z; Ding D; Yan H; Sun E; Jia X
Nutr Cancer; 2014; 66(4):682-9. PubMed ID: 24738693
[TBL] [Abstract][Full Text] [Related]
32. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
[TBL] [Abstract][Full Text] [Related]
33. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Tchaicha J; Kikuchi E; Wong KK; Kufe D
Clin Cancer Res; 2014 Nov; 20(21):5423-34. PubMed ID: 25189483
[TBL] [Abstract][Full Text] [Related]
34. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
35. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
36. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
37. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Zhang W; Zhang W; Wang L; Zheng J; Xiao F
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641
[TBL] [Abstract][Full Text] [Related]
38. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Zhu X; Jiang H; Li J; Xu J; Fei Z
Med Sci Monit; 2016 Apr; 22():1435-41. PubMed ID: 27125283
[TBL] [Abstract][Full Text] [Related]
39. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.
Zhang J; Qu Z; Yao H; Sun L; Harata-Lee Y; Cui J; Aung TN; Liu X; You R; Wang W; Hai L; Adelson DL; Lin L
Biomed Pharmacother; 2019 Oct; 118():109169. PubMed ID: 31310954
[TBL] [Abstract][Full Text] [Related]
40. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
